RESEARCH MONOGRAPH · KDC-MN-135

Oxytocin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

77/100

An established workhorse hormone with a complicated reputation in social neuroscience and a much better one in obstetrics

Oxytocin is one of those compounds where the established uses (obstetric labor augmentation, milk ejection reflex, postpartum hemorrhage control) are textbook well-understood, and then there's the social neuroscience literature that has become a methodological cautionary tale. Both pictures are true at the same time.

On the obstetric side the pharmacology is clean. Cyclic nonapeptide, posterior pituitary release, OXTR Gq-coupled signaling driving uterine smooth muscle contraction and myoepithelial milk ejection in mammary tissue. Half-life is short (a few minutes), which is why clinical use is by continuous infusion. Decades of clinical experience, very well-characterized PK/PD.

On the central nervous system side, this is where it gets messy. The intranasal oxytocin literature exploded in the 2000s and 2010s with claims about trust, social bonding, autism therapeutics, pair bonding, you name it. A lot of those studies didnt replicate. The Walum and Young 2018 critical review laid out methodological problems pretty clearly: small samples, frequent failures to replicate, uncertain CSF penetration after intranasal administration, and a tendency to interpret modest behavioral effects through whatever theoretical lens the lab favored.

What we like: the peripheral biology is gold-standard pharmacology. The receptor structure is solved, the signaling is mapped, the obstetric use is one of the cleanest examples of peptide hormone clinical translation. As a research tool for OXTR pharmacology it's a workhorse.

What we dont like: the social-effects literature is overhyped and the replications are bad. The CNS penetration story for intranasal administration is unsettled (some CSF data exists, some doesnt, and the brain regions where it matters likely receive endogenous oxytocin through different routes than exogenous nasal). We'd be cautious about anchoring on the behavioral effect sizes published in the high-citation papers.

Mechanism is well-mapped peripherally. Centrally: OXTR distribution is known (amygdala, nucleus accumbens, PVN), but the network effects of exogenous oxytocin remain partly speculative.

Sourcing: short cyclic peptide with a disulfide bridge, manufactured at scale for decades, pharmaceutical grade is widely available and research-grade vendors are reliable. Just verify the disulfide formed correctly, because reduced linear oxytocin is inactive.

Respect the peripheral pharmacology, hedge on the social neuroscience hype.

Evidence: 90
Mechanism: 85
Reliability: 70
Safety: 80
Sourcing: 88
Value: 75
Signal: 55
Staying power: 70

Plain-language summary Intrigue 72 / 100

Oxytocin is the social bonding and childbirth hormone, a 9-amino-acid peptide. Used clinically to induce labor and control postpartum bleeding. Off-label and research interest in social bonding, autism spectrum disorders, and PTSD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous nonapeptide neuropeptide/hormone

An endogenous nonapeptide produced in the hypothalamus and released by the posterior pituitary, with maternal, social bonding, and anxiolytic effects.

Abstract

Oxytocin (CAS 50-56-6; molecular formula C43H66N12O12S2; molecular weight 1007.19) is an endogenous nonapeptide hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released systemically by the posterior pituitary. The compound is FDA-approved for labor induction and postpartum hemorrhage (intravenous). Beyond reproductive applications, intranasal oxytocin has been studied extensively for autism spectrum disorder, social anxiety, PTSD, and pair bonding research, with mixed clinical results. Mechanism is oxytocin receptor (OTR) agonism. Pharmacokinetics: plasma half-life ~3 to 6 minutes; central CNS penetration after intranasal administration is debated. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Oxytocin receptor agonist. Maternal, social bonding, anxiolytic effects (CNS); uterine contraction and lactation (peripheral).

Reported research dose ranges

Reported research dose ranges in the literature.

References

Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-135

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Oxytocin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs